相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Management of Nonresponse to Rituximab in Rheumatoid Arthritis Predictors and Outcome of Re-treatment
E. M. Vital et al.
ARTHRITIS AND RHEUMATISM (2010)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis.
John H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al
Manuel Ramos-Casals et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe
R. Cervera et al.
LUPUS (2009)
Rituximab in systemic lupus erythematosus A systematic review of off-label use in 188 cases
M. Ramos-Casals et al.
LUPUS (2009)
Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus
D. Albert et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study
S. Dass et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Highly Sensitive B Cell Analysis Predicts Response to Rituximab Therapy in Rheumatoid Arthritis
Shouvik Dass et al.
ARTHRITIS AND RHEUMATISM (2008)
Mechanisms of disease: Systemic lupus erythematosus
Anisur Rahman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response
G. Cambridge et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy
Jennifer H. Anolik et al.
ARTHRITIS AND RHEUMATISM (2007)
B cell depletion therapy in systemic lupus erythematosus: Longterm follow-up and predictors of response
Kristine P. Ng et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients
MJ Leandro et al.
RHEUMATOLOGY (2005)
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
P Moreton et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
B cell depletion as a novel treatment for systemic lupus erythematosus - A phase I/II dose-escalation trial of rituximab
RJ Looney et al.
ARTHRITIS AND RHEUMATISM (2004)
分享论文
